(Rac)-Tenofovir-d6

(Rac)-Tenofovir-d6

• CAS Number: 1020719-94-1
• UNSPSC Description: (Rac)-Tenofovir-d6 is a labelled racemic Tenofovir. Tenofovir (GS 1278) is a nucleotide reverse transcriptase inhibitor to treat HIV and chronic Hepatitis B (HBV)[1].
• Target Antigen: HBV; HIV; Reverse Transcriptase
• Type: Isotope-Labeled Compounds
• Related Pathways: Anti-infection
• Applications: COVID-19-anti-virus
• Field of Research: Infection
• Purity: 99.82
• Solubility: 10 mM in DMSO
• Smiles: OP(O)(COC(C([2H])([2H])N1C=NC2=C(N)N=CN=C12)([2H])C([2H])([2H])[2H])=O
• Molecular Weight: 293.25
• References & Citations: [1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53(2):211-216.|[2]Murphy RA, et al. Establishment of HK-2 Cells as a Relevant Model to Study Tenofovir-Induced Cytotoxicity. Int J Mol Sci. 2017 Mar 1;18(3).|[3]Musumeci G, et al. M48U1 and Tenofovir combination synergistically inhibits HIV infection in activated PBMCs and human cervicovaginal histocultures. Sci Rep. 2017 Feb 1;7:41018.|[4]Wahl A, et al. Predicting HIV Pre-exposure Prophylaxis Efficacy for Women using a Preclinical Pharmacokinetic-Pharmacodynamic In Vivo Model. Sci Rep. 2017 Feb 1;7:41098.|[5]Menne S, Cote PJ, Korba BE, Antiviral effect of oral administration of tenofovir disoproxil fumarate in woodchucks with chronic woodchuck hepatitis virus infection. Antimicrob Agents Chemother. 2005 Jul;49(7):2720-8.
• Shipping Conditions: Blue Ice
• Storage Conditions: -20°C (Powder, protect from light)
• Clinical Information: No Development Reported